Skip to content

Study · Animal study (in vivo) · wistar rat · 2013

4 results

Effects of thymosin β4 on the bone formation of calvarial defects in rats.

Adachi K, Matsuo K, Akasaki Y, Kanao M, Maeda T, Ishikawa A, Hosokawa R

Journal of prosthodontic research13 Mar 2013Cited by 5 (Europe PMC)

PMID23490448 (opens in a new tab)DOI10.1016/j.jpor.2013.01.008 (opens in a new tab)PepBankPUB-23490448
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with calvarial defects, synthetic partial TB4 peptides increased new bone formation versus control, with and without atelocollagen sponges.

    In plain wordsIn rats with skull bone defects, TB4 peptides led to more new bone than control, with or without sponges.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseNew bone formation in calvarial defect
    Study

    Wistar ratn: not reported in source

    5 mm calvarial bone defect
    Comparator
    Control (phosphate-buffered saline)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intraperitonealAs given in this study (Wistar rat).

    Source sentences

    Summary
    In both models, with or without atelocollagen sponges, new bone formation was significantly greater in the TB4 group than in the control group.
    1 context sentence
    Summary · context
    In each experimental model, bone formation in calvarial defects was compared between the group receiving synthetic partial peptides of TB4 intraperitoneally (TB group) and the control group, which received an equivalent amount of phosphate-buffered saline.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In some TB4-treated rats, newly formed bone almost covered the whole 5 mm defect by postoperative day 20.

    In plain wordsIn some rats given TB4 peptides, new bone almost covered the whole skull defect by day 20.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCoverage of bone defect by new bone at day 20
    Study

    Wistar ratn: not reported in source

    5 mm calvarial bone defect
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intraperitonealAs given in this study (Wistar rat).

    Source sentences

    Summary
    In some TB4 group individuals, the entire bone defect region of diameter 5mm was almost covered with newly formed bone by postoperative day 20.
    1 context sentence
    Summary · context
    In each experimental model, bone formation in calvarial defects was compared between the group receiving synthetic partial peptides of TB4 intraperitoneally (TB group) and the control group, which received an equivalent amount of phosphate-buffered saline.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats with calvarial defects, TB4 increased the number of osterix-positive cells at day 5.

    In plain wordsIn rats with skull bone defects, TB4 peptides gave more osterix-positive cells, a marker of bone-forming cells.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseOsterix-positive cells at day 5
    Study

    Wistar ratn: not reported in source

    5 mm calvarial bone defect
    Comparator
    Control (phosphate-buffered saline)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intraperitonealAs given in this study (Wistar rat).

    Source sentences

    Summary
    Immunostaining revealed a significant number of osterix-positive cells in the TB4 group.
    1 context sentence
    Summary · context
    In each experimental model, bone formation in calvarial defects was compared between the group receiving synthetic partial peptides of TB4 intraperitoneally (TB group) and the control group, which received an equivalent amount of phosphate-buffered saline.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    In rats with calvarial defects, bone-related gene expression on day 10 did not differ significantly between the TB4 and control groups.

    In plain wordsIn rats with skull bone defects, short pieces (fragments) of Tβ4 caused no clear change in bone-related gene activity at day 10.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeBone-related gene expression at day 10
    Study

    Wistar ratn: not reported in source

    5 mm calvarial bone defect
    Comparator
    Control (phosphate-buffered saline)
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    On postoperative day 10, the expression levels of bone-related genes were analyzed by RT-PCR, which showed no statistically significant differences between the two groups.
    1 context sentence
    Summary · context
    In each experimental model, bone formation in calvarial defects was compared between the group receiving synthetic partial peptides of TB4 intraperitoneally (TB group) and the control group, which received an equivalent amount of phosphate-buffered saline.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.